Long-term follow-up on cancer treatment effects and patient quality of life
Non-interventional and Longitudinal Study to Evaluate a List of Anticancer Drugs Under Real Conditions of Use and Measure the Quality of Life of Patients Treated at Rafaël Institute
This study is trying to see how new cancer treatments affect patients' lives and well-being over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institut Rafael Academic / other |
| Locations | 1 site (Levallois-Perret, Institut Rafael) |
| Trial ID | NCT06317714 on ClinicalTrials.gov |
What this trial studies
This observational study aims to establish a registry that collects data on the safety and effectiveness of innovative anticancer drugs in real-life settings while also measuring the quality of life of patients undergoing these treatments. The Rafael Institute focuses on a patient-centered approach, emphasizing the importance of personalized care and continuous support from a multidisciplinary team. By documenting the relationship between treatment side effects and quality of life, the study seeks to enhance the overall management of cancer patients and address their needs more effectively.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are receiving innovative or expensive anticancer therapies at the Rafael Institute.
Not a fit: Patients under 18 years old or those unable to provide consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of the quality of life for cancer patients undergoing treatment.
How similar studies have performed: Other studies focusing on quality of life in cancer patients have shown success, indicating that this approach is valuable and relevant.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age equal to or greater than 18 years (adult) * Patients treated with an anticancer drug included in the list of innovative/expensive therapies (protocol appendix) * Patients benefiting from non-pharmacological treatment at the Rafael Institute * Who understands the French language Exclusion Criteria: * \< 18 years old * Patient deprived of liberty, under guardianship or unable to give consent
Where this trial is running
Levallois-Perret, Institut Rafael
- Institute Rafaël — Levallois-Perret, Institut Rafael, France (Recruiting)
Study contacts
- Study coordinator: Alain TOLEDANO, MD
- Email: alain.toledano@horg.fr
- Phone: + 33 (0)1 84 00 70 07
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.